Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Nystatin

Classification: B

Drug products: Adiclair, Biofanal, FLAGYL Comp. emätinpuikko, Mycostatin, Mycostatin®, Mykundex Mono Salbe, Nystaderm, Nystatin acis, Nystatin fem JENAPHARM, Nystatin Orifarm, Nystimex, Nyvigan

ATC code: A07AA02, D01AA01, G01AA01, G01AF01

Substances: nystatin

Summary

Published controlled studies on differences between men and women in effect, safety and pharmacokinetics of nystatin are lacking.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of nystatin have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of nystatin have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of nystatin have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

In some countries, nystatin is available as vaginal preparations. They may damage latex contraceptives and thus additional contraceptives may be needed [1].

Updated: 2020-08-28

Date of litterature search: 2015-06-02

References

Martindale: The Complete Drug Reference. Pharmaceutical Press.
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk

Authors: Linnéa Karlsson Lind, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson